ABBOTT PARK, Ill., and SAN RAMON, Calif., Oct. 19 /PRNewswire-FirstCall/
-- Abbott (NYSE: ABT) and BioGenex Laboratories today announced an agreement
to distribute and market a new system that will fully automate molecular
diagnostic tests that employ Abbott's proprietary Fluorescence in situ
Hybridization (FISH) technology.
The system is designed to automate all of the assay steps required to
perform Abbott's FISH-based tests, including the application, removal and
re-application of the coverslip resulting in a completely finished slide that
is ready to go directly on the microscope for review. It is expected to be
introduced to the market in the near future, pending regulatory clearance.
"The increasing demand for molecular testing is putting pressure on
clinical laboratories to process these tests more quickly," said Edward L.
Michael, president, Abbott Molecular Diagnostics, Abbott. "By further
automating our FISH technology, we can help our customers keep up with the
workflow demands, save labor costs, further enhance test reliability and,
ultimately, improve patient care."
"We are pleased that Abbott has elected to distribute our products
integrated with their FISH applications worldwide," said Krishan Kalra, Ph.D.,
chairman and CEO, BioGenex. "This underscores application of BioGenex
technology for harnessing the power of genomics to accelerate the pace of
molecular medicine. Our partnership offers an excellent opportunity to
co-develop and commercialize workflow solutions for a multitude of diagnostic
Under the terms of the agreement, Abbott has co-exclusive rights with
BioGenex to market and distribute the new system worldwide in the FISH field.
Abbott and BioGenex will collaborate to further develop automated solutions
for FISH applications. As part of the agreement, BioGenex has received a
multi-year minimum volume commitment and an upfront payment toward future
purchases of systems.
FISH technology provides the ability to see multiple chromosomal
abnormalities simultaneously in a single cell and to visually assess these
genetic abnormalities in patient specimens. FISH-based tests use DNA probes
labeled with colored fluorescent tags that bind to specific gene sequences on
human chromosomes. These probes can reveal amplification of gene copy number
or the rearrangement of large genetic structures, two genetic abnormalities
that underlie certain cancers and other medical conditions. Abbott's
FISH-based tests include PathVysion(R), which is used to detect amplification
of the HER-2 gene and as an aid in determining whether a patient is an
appropriate candidate for Herceptin(R) (trastuzumab) therapy for breast
cancer, and Vysis UroVysion(R), for monitoring for the recurrence of bladder
BioGenex, a technology leader in molecular pathology, provides Total
Solution for complete automation of cell and tissue testing. The company
offers a broad range of reagents and systems to streamline and standardize
cellular and molecular diagnostics. BioGenex's products are designed for high
throughput at a low cost of ownership, providing ease of use and maximum
flexibility for clinical diagnostics, life science research, and drug
BioGenex's news releases and other information are available at
About Abbott Molecular Diagnostics
Abbott's rapidly growing molecular diagnostics business provides
physicians with critical information based on the early detection of pathogens
and subtle changes in patients' genes and chromosomes, allowing for earlier
diagnosis, selection of appropriate therapies and monitoring of disease
progression. The business includes instruments and reagents used to conduct
sophisticated analysis of patient DNA and RNA.
Abbott is a global, broad-based health care company devoted to the
discovery, development, manufacture and marketing of pharmaceuticals and
medical products, including nutritionals, devices and diagnostics. The
company employs more than 55,000 people and markets its products in more than
Abbott's news releases and other information are available on the
company's Web site at http://www.abbott.com .